Tags : Ready-To-Use Insulin

Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval

Tuba Khan July 23, 2019

Shots: The US FDA has granted approval to Myxredlin as the first ready-to-use insulin for IV infusion in the hospital with an extended shelf-life of 30 days @25◦C or 24 […]readmore

Tags : Ready-To-Use Insulin

Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Ready-To-Use Insulin

Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company